Across TCGA pan-cancer cohorts, TRBJ2-4 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TRBJ2-4 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TRBJ2-4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRBJ2-4 expression acts as an unfavorable survival marker.

STAD are the cancer types where TRBJ2-4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.183	0.677	.004	24	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: TRBJ2-4 tumor-vs-normal RNA expression · all TRBJ2-4 data types